FDA Approves Xpovio Triple Combo for Previously Treated Myeloma
The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment…
Patricia Inácio, PhD, science writer — 
Articles by Patricia Inácio
Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets
Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company…
Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU
Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and …
Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against…
FDA Grants Fast Track Designation to ‘Off-the-shelf’ CAR T-cell Therapy
The U.S. Food and Drug Administration has granted fast track designation to PBCAR269A, Precision BioSciences‘ donor-derived CAR T-cell therapy for the treatment…
Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority review to Oncopeptide’s application seeking accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone…
Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1/2a trial investigating Precision BioSciences‘ new CAR T-cell therapy candidate, PBCAR269A, for people with relapsed…
FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan…
Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled
A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled,…
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000…
